Results 61 to 70 of about 15,263 (254)

Effectiveness of transitioning from omalizumab to dupilumab in chronic spontaneous urticaria patients with inadequate response to omalizumab

open access: yesWorld Allergy Organization Journal
Dupilumab is effective for chronic spontaneous urticaria (CSU), but its clinical benefit of switching to dupilumab in omalizumab-resistant CSU remains unclear.This prospective pilot study evaluated the effectiveness of dupilumab in 12 CSU patients whose ...
Koremasa Hayama, M.D., Ph.D.   +2 more
doaj   +1 more source

Treatment of Netherton syndrome with dupilumab

open access: yes, 2022
Background Netherton syndrome (NS) is a rare autosomal recessive skin disease caused by loss of function mutations in SPINK5 gene (serine protease inhibitor of kazal type 5) encoding LEKTI (lymphoepitelial kazal-type-related inhibitor).
Cecilia Schenetti   +11 more
core   +1 more source

Severe pediatric asthma therapy: Dupilumab

open access: yes, 2022
Severe asthma is a rare disease affecting <5% of children with asthma. This group of patients account for about 50% of the costs of healthcare for children with asthma. Nowadays, several biological agents are available for pediatric severe asthma. One
Michele Piazza   +3 more
core   +2 more sources

Knowledge and practice regarding eosinophilic gastrointestinal disorders other than eosinophilic esophagitis among pediatric gastroenterologists of the Latin American Society for Pediatric Gastroenterology, Hepatology, and Nutrition

open access: yesJPGN Reports, EarlyView.
Abstract Objective Evaluating clinical practices in the management of non‐esophageal eosinophilic gastrointestinal disorders (non‐EoE EGIDs) among pediatric gastroenterologists in Latin America. Methods A cross‐sectional descriptive study was conducted using a survey distributed via the REDCap platform.
Sofia Paz   +17 more
wiley   +1 more source

The use of dupilumab in severe atopic dermatitis during pregnancy: a case report

open access: yesAllergy, Asthma & Clinical Immunology, 2022
Background Atopic dermatitis is a common chronic skin disease that can occur in pregnancy. Current treatments include topical and systemic glucocorticoids and cyclosporine.
Nabeel H. Akhtar   +4 more
doaj   +1 more source

Type II achalasia unmasked by EndoFLIP and high‐resolution manometry in a child with eosinophilic esophagitis

open access: yesJPGN Reports, EarlyView.
ABSTRACT Eosinophilic esophagitis (EoE) is a chronic immune‐mediated disease characterized by esophageal dysfunction and eosinophilic inflammation. Persistent dysphagia despite histologic remission should prompt evaluation for alternative etiologies. A 10‐year‐old male with asthma and eczema presented with progressive solid food dysphagia, daily non ...
Rasha Abi Radi Abou Jaoudeh   +2 more
wiley   +1 more source

Characterizing the Epithelial Transcriptome of Type‐2 High Chronic Rhinosinusitis

open access: yes
International Forum of Allergy &Rhinology, EarlyView.
Brian Cameron   +7 more
wiley   +1 more source

The Role of Artificial Intelligence in Modern Allergology: A Review of Applications in Diagnosis, Prediction, and Management

open access: yesJEADV Clinical Practice, EarlyView.
ABSTRACT Artificial Intelligence is rapidly transforming allergology by enhancing diagnosis, risk prediction, automation, patient communication, education, and therapy development. Machine learning approaches, including convolutional neural networks, recurrent architectures, and transformer‐based models, enable analysis of complex datasets from ...
Sebastian Seurig   +2 more
wiley   +1 more source

Dupilumab for recalcitrant Kimura disease

open access: yes, 2022
Dupilumab for recalcitrant Kimura ...
Querzoli, Giulia   +4 more
core   +1 more source

Successful Co‐Administration of Secukinumab and Dupilumab in a Patient With Psoriasis and Paradoxical Atopic Dermatitis

open access: yesJEADV Clinical Practice, EarlyView.
ABSTRACT Paradoxical atopic dermatitis (AD) can arise during biologic therapy for psoriasis due to an immune‐axis imbalance. We describe a 47‐year‐old man who developed severe AD while receiving secukinumab, which was successfully managed with the addition of dupilumab, allowing long‐term control of both diseases.
So Yun Park   +6 more
wiley   +1 more source

Home - About - Disclaimer - Privacy